195 related articles for article (PubMed ID: 25635530)
1. Ibrutinib has some activity in Richter's syndrome.
Giri S; Hahn A; Yaghmour G; Martin MG
Blood Cancer J; 2015 Jan; 5(1):e277. PubMed ID: 25635530
[No Abstract] [Full Text] [Related]
2. Ibrutinib-induced rapid response in chemotherapy-refractory Richter's syndrome.
Fischer A; Bastian S; Cogliatti S; Mey U; Saub J; Schanz U; Padberg B; Hohloch K
Hematol Oncol; 2018 Feb; 36(1):370-371. PubMed ID: 28681549
[No Abstract] [Full Text] [Related]
3. Coexistence of chronic myeloid leukemia and diffuse large B-cell lymphoma with antecedent chronic lymphocytic leukemia: a case report and review of the literature.
Abuelgasim KA; Rehan H; Alsubaie M; Al Atwi N; Al Balwi M; Alshieban S; Almughairi A
J Med Case Rep; 2018 Mar; 12(1):64. PubMed ID: 29524963
[TBL] [Abstract][Full Text] [Related]
4. Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study.
Younes A; Brody J; Carpio C; Lopez-Guillermo A; Ben-Yehuda D; Ferhanoglu B; Nagler A; Ozcan M; Avivi I; Bosch F; Caballero Barrigón MD; Hellmann A; Kuss B; Ma DDF; Demirkan F; Yağci M; Horowitz NA; Marlton P; Cordoba R; Wrobel T; Buglio D; Streit M; Hodkinson BP; Schaffer M; Alvarez J; Ceulemans R; Balasubramanian S; de Jong J; Wang SS; Fourneau N; Jurczak W
Lancet Haematol; 2019 Feb; 6(2):e67-e78. PubMed ID: 30642819
[TBL] [Abstract][Full Text] [Related]
5. Haematological cancer: Richter's transformation in CLL-a distinct lymphoma.
Jain P; Young KH
Nat Rev Clin Oncol; 2014 Jan; 11(1):6-8. PubMed ID: 24281057
[TBL] [Abstract][Full Text] [Related]
6. EBV-positive Richter's syndrome with laboratory features of Burkitt's lymphoma, in Ibrutinib-treated chronic lymphocytic leukemia.
Hussaini MO; Rehman A; Chavez JC; Pinilla-Ibarz J; Horna P
Leuk Lymphoma; 2017 Jul; 58(7):1753-1756. PubMed ID: 27852142
[No Abstract] [Full Text] [Related]
7. Atypical primary cutaneous cryptococcosis during ibrutinib therapy for chronic lymphocytic leukemia.
Peri AM; Rossio R; Tafuri F; Benzecry V; Grancini A; Reda G; Bandera A; Peyvandi F
Ann Hematol; 2019 Dec; 98(12):2847-2849. PubMed ID: 31741032
[No Abstract] [Full Text] [Related]
8. Seasonal Influenza Vaccination in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib.
Sun C; Gao J; Couzens L; Tian X; Farooqui MZ; Eichelberger MC; Wiestner A
JAMA Oncol; 2016 Dec; 2(12):1656-1657. PubMed ID: 27533065
[No Abstract] [Full Text] [Related]
9. Deciphering Ibrutinib Resistance in Chronic Lymphocytic Leukemia.
Lenz G
J Clin Oncol; 2017 May; 35(13):1451-1452. PubMed ID: 28291389
[No Abstract] [Full Text] [Related]
10. Ibrutinib rash in a patient with 17p del chronic lymphocytic leukemia.
Mannis G; Wu D; Dea T; Mauro T; Hsu G
Am J Hematol; 2015 Feb; 90(2):179. PubMed ID: 24890909
[No Abstract] [Full Text] [Related]
11. Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice.
Hampel PJ; Ding W; Call TG; Rabe KG; Kenderian SS; Witzig TE; Muchtar E; Leis JF; Chanan-Khan AA; Koehler AB; Fonder AL; Schwager SM; Slager SL; Shanafelt TD; Kay NE; Parikh SA
Leuk Lymphoma; 2019 Nov; 60(11):2712-2719. PubMed ID: 31014142
[TBL] [Abstract][Full Text] [Related]
12. De novo CD5-positive and Richter's syndrome-associated diffuse large B cell lymphomas are genotypically distinct.
Matolcsy A; Chadburn A; Knowles DM
Am J Pathol; 1995 Jul; 147(1):207-16. PubMed ID: 7541611
[TBL] [Abstract][Full Text] [Related]
13. A simplified prognostic index for chronic lymphocytic leukemia treated with ibrutinib: Results from a multicenter retrospective cohort study.
Gordon MJ; Sitlinger A; Salous T; Alqahtani H; Churnetski M; Rivera X; Wisniewski P; Cohen J; Patel K; Shadman M; Choi M; Hill B; Stephens D; Persky D; Brander D; Danilov AV
Leuk Res; 2020 Feb; 89():106302. PubMed ID: 31982152
[No Abstract] [Full Text] [Related]
14. Addition of venetoclax at time of progression in ibrutinib-treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare.
Hampel PJ; Call TG; Ding W; Muchtar E; Kenderian SS; Wang Y; Leis JF; Witzig TE; Koehler AB; Fonder AL; Schwager SM; Rabe KG; Van Dyke DL; Braggio E; Slager SL; Kay NE; Parikh SA
Am J Hematol; 2020 Mar; 95(3):E57-E60. PubMed ID: 31788844
[No Abstract] [Full Text] [Related]
15. Ventricular arrhythmias and sudden death in patients taking ibrutinib.
Lampson BL; Yu L; Glynn RJ; Barrientos JC; Jacobsen ED; Banerji V; Jones JA; Walewska R; Savage KJ; Michaud GF; Moslehi JJ; Brown JR
Blood; 2017 May; 129(18):2581-2584. PubMed ID: 28223277
[No Abstract] [Full Text] [Related]
16. Ibrutinib induced acute tubular injury: A case series and review of the literature.
Manohar S; Bansal A; Wanchoo R; Sakhiya V; Lucia S; Jhaveri KD
Am J Hematol; 2019 Sep; 94(9):E223-E225. PubMed ID: 31148235
[No Abstract] [Full Text] [Related]
17. Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice.
Finnes HD; Chaffee KG; Call TG; Ding W; Kenderian SS; Bowen DA; Conte M; McCullough KB; Merten JA; Bartoo GT; Smith MD; Leis J; Chanan-Khan A; Schwager SM; Slager SL; Kay NE; Shanafelt TD; Parikh SA
Leuk Lymphoma; 2017 Jun; 58(6):1376-1383. PubMed ID: 27820970
[TBL] [Abstract][Full Text] [Related]
18. The HELIOS trial protocol: a phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia.
Hallek M; Kay NE; Osterborg A; Chanan-Khan AA; Mahler M; Salman M; Wan Y; Sun S; Zhuang SH; Howes A
Future Oncol; 2015; 11(1):51-9. PubMed ID: 24901734
[TBL] [Abstract][Full Text] [Related]
19. Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2.
Barr PM; Robak T; Owen C; Tedeschi A; Bairey O; Bartlett NL; Burger JA; Hillmen P; Coutre S; Devereux S; Grosicki S; McCarthy H; Li J; Simpson D; Offner F; Moreno C; Zhou C; Styles L; James D; Kipps TJ; Ghia P
Haematologica; 2018 Sep; 103(9):1502-1510. PubMed ID: 29880603
[TBL] [Abstract][Full Text] [Related]
20. Spatial clonal evolution leading to ibrutinib resistance and disease progression in chronic lymphocytic leukemia.
Kiss R; Alpár D; Gángó A; Nagy N; Eyupoglu E; Aczél D; Matolcsy A; Csomor J; Mátrai Z; Bödör C
Haematologica; 2019 Jan; 104(1):e38-e41. PubMed ID: 30262564
[No Abstract] [Full Text] [Related]
[Next] [New Search]
